vs
DigitalOcean Holdings, Inc.（DOCN）与Pacira BioSciences, Inc.（PCRX）财务数据对比。点击上方公司名可切换其他公司
DigitalOcean Holdings, Inc.的季度营收约是Pacira BioSciences, Inc.的1.4倍（$242.4M vs $177.4M），DigitalOcean Holdings, Inc.净利率更高（10.6% vs 1.6%，领先8.9%），DigitalOcean Holdings, Inc.同比增速更快（18.3% vs 5.0%），过去两年DigitalOcean Holdings, Inc.的营收复合增速更高（14.5% vs -0.2%）
DigitalOcean Holdings, Inc.是美国跨国科技企业及云服务提供商，总部位于美国科罗拉多州布鲁姆菲尔德，在全球布局15个数据中心，面向开发者、初创企业及中小微企业提供稳定易用的云基础设施即服务平台，助力各类技术团队高效开展业务。
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
DOCN vs PCRX — 直观对比
营收规模更大
DOCN
是对方的1.4倍
$177.4M
营收增速更快
DOCN
高出13.3%
5.0%
净利率更高
DOCN
高出8.9%
1.6%
两年增速更快
DOCN
近两年复合增速
-0.2%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $242.4M | $177.4M |
| 净利润 | $25.7M | $2.9M |
| 毛利率 | 58.7% | — |
| 营业利润率 | 16.0% | 3.9% |
| 净利率 | 10.6% | 1.6% |
| 营收同比 | 18.3% | 5.0% |
| 净利润同比 | 40.5% | — |
| 每股收益（稀释后） | $0.23 | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DOCNPCRX
| Q1 26 | — | $177.4M | ||
| Q4 25 | $242.4M | $196.9M | ||
| Q3 25 | $229.6M | $179.5M | ||
| Q2 25 | $218.7M | $181.1M | ||
| Q1 25 | $210.7M | $168.9M | ||
| Q4 24 | $204.9M | $187.3M | ||
| Q3 24 | $198.5M | $168.6M | ||
| Q2 24 | $192.5M | $178.0M |
净利润DOCNPCRX
| Q1 26 | — | $2.9M | ||
| Q4 25 | $25.7M | — | ||
| Q3 25 | $158.4M | $5.4M | ||
| Q2 25 | $37.0M | $-4.8M | ||
| Q1 25 | $38.2M | $4.8M | ||
| Q4 24 | $18.3M | — | ||
| Q3 24 | $32.9M | $-143.5M | ||
| Q2 24 | $19.1M | $18.9M |
毛利率DOCNPCRX
| Q1 26 | — | — | ||
| Q4 25 | 58.7% | 79.5% | ||
| Q3 25 | 59.6% | 80.9% | ||
| Q2 25 | 59.9% | 77.4% | ||
| Q1 25 | 61.4% | 79.7% | ||
| Q4 24 | 57.1% | 78.7% | ||
| Q3 24 | 60.2% | 76.9% | ||
| Q2 24 | 61.0% | 75.1% |
营业利润率DOCNPCRX
| Q1 26 | — | 3.9% | ||
| Q4 25 | 16.0% | 1.2% | ||
| Q3 25 | 19.6% | 3.5% | ||
| Q2 25 | 16.3% | 4.7% | ||
| Q1 25 | 17.9% | 1.2% | ||
| Q4 24 | 15.9% | 13.2% | ||
| Q3 24 | 12.4% | -82.8% | ||
| Q2 24 | 11.6% | 15.9% |
净利率DOCNPCRX
| Q1 26 | — | 1.6% | ||
| Q4 25 | 10.6% | — | ||
| Q3 25 | 69.0% | 3.0% | ||
| Q2 25 | 16.9% | -2.7% | ||
| Q1 25 | 18.1% | 2.8% | ||
| Q4 24 | 8.9% | — | ||
| Q3 24 | 16.6% | -85.1% | ||
| Q2 24 | 9.9% | 10.6% |
每股收益（稀释后）DOCNPCRX
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.23 | $0.05 | ||
| Q3 25 | $1.51 | $0.12 | ||
| Q2 25 | $0.39 | $-0.11 | ||
| Q1 25 | $0.39 | $0.10 | ||
| Q4 24 | $0.21 | $0.38 | ||
| Q3 24 | $0.33 | $-3.11 | ||
| Q2 24 | $0.20 | $0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $254.5M | $144.3M |
| 总债务越低越好 | $1.3B | — |
| 股东权益账面价值 | $-28.7M | $653.9M |
| 总资产 | $1.8B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DOCNPCRX
| Q1 26 | — | $144.3M | ||
| Q4 25 | $254.5M | $238.4M | ||
| Q3 25 | $236.6M | $246.3M | ||
| Q2 25 | $387.7M | $445.9M | ||
| Q1 25 | $360.4M | $493.6M | ||
| Q4 24 | $428.4M | $484.6M | ||
| Q3 24 | $439.9M | $453.8M | ||
| Q2 24 | $443.1M | $404.2M |
总债务DOCNPCRX
| Q1 26 | — | — | ||
| Q4 25 | $1.3B | $372.2M | ||
| Q3 25 | $1.3B | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | $1.5B | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益DOCNPCRX
| Q1 26 | — | $653.9M | ||
| Q4 25 | $-28.7M | $693.1M | ||
| Q3 25 | $-69.6M | $727.2M | ||
| Q2 25 | $-175.2M | $757.8M | ||
| Q1 25 | $-210.7M | $798.5M | ||
| Q4 24 | $-203.0M | $778.3M | ||
| Q3 24 | $-211.7M | $749.6M | ||
| Q2 24 | $-253.8M | $879.3M |
总资产DOCNPCRX
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.8B | $1.3B | ||
| Q3 25 | $1.7B | $1.3B | ||
| Q2 25 | $1.7B | $1.5B | ||
| Q1 25 | $1.6B | $1.6B | ||
| Q4 24 | $1.6B | $1.6B | ||
| Q3 24 | $1.5B | $1.5B | ||
| Q2 24 | $1.5B | $1.6B |
负债/权益比DOCNPCRX
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $57.3M | — |
| 自由现金流经营现金流 - 资本支出 | $31.1M | — |
| 自由现金流率自由现金流/营收 | 12.8% | — |
| 资本支出强度资本支出/营收 | 10.8% | — |
| 现金转化率经营现金流/净利润 | 2.23× | — |
| 过去12个月自由现金流最近4个季度 | $180.5M | — |
8季度趋势，按日历期对齐
经营现金流DOCNPCRX
| Q1 26 | — | — | ||
| Q4 25 | $57.3M | $43.7M | ||
| Q3 25 | $95.8M | $60.8M | ||
| Q2 25 | $92.4M | $12.0M | ||
| Q1 25 | $64.1M | $35.5M | ||
| Q4 24 | $71.3M | $33.1M | ||
| Q3 24 | $73.4M | $53.9M | ||
| Q2 24 | $71.3M | $53.2M |
自由现金流DOCNPCRX
| Q1 26 | — | — | ||
| Q4 25 | $31.1M | $43.5M | ||
| Q3 25 | $88.0M | $57.0M | ||
| Q2 25 | $59.3M | $9.3M | ||
| Q1 25 | $2.1M | $26.9M | ||
| Q4 24 | $26.1M | $31.0M | ||
| Q3 24 | $16.0M | $49.8M | ||
| Q2 24 | $39.5M | $51.6M |
自由现金流率DOCNPCRX
| Q1 26 | — | — | ||
| Q4 25 | 12.8% | 22.1% | ||
| Q3 25 | 38.3% | 31.7% | ||
| Q2 25 | 27.1% | 5.1% | ||
| Q1 25 | 1.0% | 15.9% | ||
| Q4 24 | 12.7% | 16.6% | ||
| Q3 24 | 8.1% | 29.6% | ||
| Q2 24 | 20.5% | 29.0% |
资本支出强度DOCNPCRX
| Q1 26 | — | — | ||
| Q4 25 | 10.8% | 0.1% | ||
| Q3 25 | 3.4% | 2.2% | ||
| Q2 25 | 15.2% | 1.5% | ||
| Q1 25 | 29.4% | 5.1% | ||
| Q4 24 | 22.1% | 1.1% | ||
| Q3 24 | 28.9% | 2.4% | ||
| Q2 24 | 16.6% | 0.9% |
现金转化率DOCNPCRX
| Q1 26 | — | — | ||
| Q4 25 | 2.23× | — | ||
| Q3 25 | 0.60× | 11.20× | ||
| Q2 25 | 2.50× | — | ||
| Q1 25 | 1.68× | 7.37× | ||
| Q4 24 | 3.91× | — | ||
| Q3 24 | 2.23× | — | ||
| Q2 24 | 3.73× | 2.82× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DOCN
| Scalers | $84.3M | 35% |
| Scalers Plus | $69.9M | 29% |
| Builders | $64.1M | 26% |
| Learners Testers And Other | $24.1M | 10% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
